Clinical Trial: Trends in the Administration of Tranexamic Acid for Postpartum Hemorrhage

U.S., Dec. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07278037) titled 'Trends in the Administration of Tranexamic Acid for Postpartum Hemorrhage' on Nov. 30.

Brief Summary: Postpartum hemorrhage (PPH) is the global leading cause of maternal death, with 20-30% of maternal deaths in Thailand linked to hemorrhage. The WOMAN Trial (2017) provided strong evidence that administering tranexamic acid (TXA)within three hours of bleeding onset lowered PPH-related mortality by 31%. Consequently, the World Health Organization (WHO) updated its guidelines, recommending TXA as part of the standard treatment package for all PPH cases. Following this, the use of TXA has been widely adopted globally and increased in Th...